- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
How a Patient Finally Resolved a Clostridioides difficile Infection
After struggling for months with a Clostridioides difficile infection, Freda Pyles traveled from her home to rural Pennsylvania to Yale-New Haven Hospital in Connecticut for the therapy that ultimately healed her.
Freda Pyles, a resident of rural Pennsylvania, spent months with a recurrent Clostridioides difficile infection in 2021 into 2022; in this interview, she describes the therapy she received at Yale-New Haven Hospital that ultimately healed her.
Transcript
Is the treatment that ultimately worked for your Clostridioides difficile a fecal transplant?
Yes, it was the only thing that worked. And I felt good the very next day. The very next day, I got up and I said to my friends that we were staying with, I said, I feel good. I feel really good. I think I can go out and do something. And our friends that are both doctors said, are you sure? I said, yes, I feel good enough to go out and do something today. So my friend and I went and got a manicure. And I didn't have any problems that whole day. We got the manicure, we went to Trader Joe's, we went to Costco, we joined our husbands for dinner. And I felt good. And the next day we were leaving, and I felt good enough to get my car and drive. I just—it was, it was such a wonderful feeling. I said, I felt good like I have never felt good before.
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG
June 12th 2025Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).
Read More
